reports
Floridienne S.A.: 1 director
A director at Floridienne S.A. bought 30 shares at 605.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
ONWARD Medical Publishes Closing of Bookbuild Offering
ONWARD Medical Publishes Closing of Bookbuild Offering NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR:...
- Jacob Mekhael
Onward Medical Raises € 50.85m gross proceeds in private placement
Onward announced the placement of 11.3m new ordinary shares in a private placement by way of an accelerated bookbuild offering at an issue price of € 4.5 per share (approx. 12.5% discount to closing price prior to deal announcement) resulting in gross proceeds of € 50.85m. Onwards cash runway is extended through at least end of 2026 (previously 1H26), assuming no drawdown of the company's debt facility with Runway Growth. The transaction was supported by existing and new, long-only and sector sp...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Wim Hoste
- Wim Lewi
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Incr...
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Successful transaction supported by strong demand from existing and new high-quality, lon...
- ING Helpdesk
Benelux Morning Notes
Aalberts: 3Q in line, FY margin now low end of guidance. Acomo: Going from strength to strength. Ahold Delhaize: New $860m distribution centre for Food Lion. Azelis: Weak 3Q25 as broadly expected, CFO to step down. Barco: Press release ahead of CMD. BE Semiconductor Industries: 3Q25 Results – Delivered on order intake. Econocom: 3Q25 organic growth down to c.3.4%, full year growth guidance confirmed. Heineken: EverGreen 2030. Kinepolis: Weak 3Q25 as expected, with Netherlands at ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Onward Medical Launches capital increase for gross proceeds of € 50m
Onward announced the launch of a capital increase by way of a bookbuild offering through a private placement with institutional investors intending to raise gross proceeds of approx. € 50m. The capital raise is expected to be anchored by multiple long-only institutions, including existing and new shareholders. Onward expects to use the net proceeds towards development of the implantable ARC-IM system (40%) and to support commercialisation of the external ARC-EX device in upper limb function in S...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR ...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Private placement is expected to be anchored by multiple long-only institutions, in...
- Guy Sips
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Guy Sips
Floridienne Monoholding in Disguise
Floridienne is a holding with full private market exposure, ESG focus, and long-term family stewardship. Floridienne transformed over the past decade from a multi-asset to a de facto mono-holding. The main driver of this transformation is the superior performance of its crown jewel BioFirst, a global leader in biocontrol benefiting from the trend toward sustainability in agriculture. Floridienne's valuation and investment thesis depend on its continued success story. We reiterate our Accumulate ...
- Jacob Mekhael
Onward Medical Preliminary 3Q25 update shows ARC-EX US commercialisati...
Onward reported a preliminary 3Q25 update, which shows that ARC-EX commercialisation in the US remains on track. With 40 ARC-EX systems sold in the US in 3Q25 (20 systems in 2Q25), we believe FY25 consensus of 150 devices is within reach if this rate of uptake continues for the remainder of the year. Looking ahead, the company previously guided it anticipates home use label expansion for ARC-EX in the US, and plans to initiate the pivotal Empower BP trial of the implantable ARC-IM system in SCI ...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accele...
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces the following key achievements in the third quarter of 2025: Commercial traction: 40 ARC-EX® Systems were sold in Q3, demonstrating continued strong commercial traction...
- ING Helpdesk
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical w...
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20 EINDHOVEN, the Netherlands, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces that BNP Paribas’ broker Portzamparc has initiated coverage with a Buy rating and a Target Price of EUR 10.20. Dave Marver, Chief Executive Officer of ONWARD Medical...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.